469 related articles for article (PubMed ID: 29605883)
21. IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia.
Pegram HJ; Purdon TJ; van Leeuwen DG; Curran KJ; Giralt SA; Barker JN; Brentjens RJ
Leukemia; 2015 Feb; 29(2):415-22. PubMed ID: 25005243
[TBL] [Abstract][Full Text] [Related]
22. In Vivo Generation of CAR T Cells Selectively in Human CD4
Agarwal S; Hanauer JDS; Frank AM; Riechert V; Thalheimer FB; Buchholz CJ
Mol Ther; 2020 Aug; 28(8):1783-1794. PubMed ID: 32485137
[TBL] [Abstract][Full Text] [Related]
23. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
24. CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia.
Zebley CC; Brown C; Mi T; Fan Y; Alli S; Boi S; Galletti G; Lugli E; Langfitt D; Metais JY; Lockey T; Meagher M; Triplett B; Talleur AC; Gottschalk S; Youngblood B
Cell Rep; 2021 Nov; 37(9):110079. PubMed ID: 34852226
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract][Full Text] [Related]
26. CD19 CAR T cell product and disease attributes predict leukemia remission durability.
Finney OC; Brakke HM; Rawlings-Rhea S; Hicks R; Doolittle D; Lopez M; Futrell RB; Orentas RJ; Li D; Gardner RA; Jensen MC
J Clin Invest; 2019 May; 129(5):2123-2132. PubMed ID: 30860496
[TBL] [Abstract][Full Text] [Related]
27. Efficient derivation of chimeric-antigen receptor-modified T
Kranz E; Kuhlmann CJ; Chan J; Kim PY; Chen ISY; Kamata M
Front Immunol; 2022; 13():877682. PubMed ID: 35967430
[TBL] [Abstract][Full Text] [Related]
28. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
29.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
30. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
Lapteva N; Gilbert M; Diaconu I; Rollins LA; Al-Sabbagh M; Naik S; Krance RA; Tripic T; Hiregange M; Raghavan D; Dakhova O; Rouce RH; Liu H; Omer B; Savoldo B; Dotti G; Cruz CR; Sharpe K; Gates M; Orozco A; Durett A; Pacheco E; Gee AP; Ramos CA; Heslop HE; Brenner MK; Rooney CM
Clin Cancer Res; 2019 Dec; 25(24):7340-7350. PubMed ID: 31558475
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
32. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
Stenger D; Stief TA; Kaeuferle T; Willier S; Rataj F; Schober K; Vick B; Lotfi R; Wagner B; Grünewald TGP; Kobold S; Busch DH; Jeremias I; Blaeschke F; Feuchtinger T
Blood; 2020 Sep; 136(12):1407-1418. PubMed ID: 32483603
[TBL] [Abstract][Full Text] [Related]
33. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
[TBL] [Abstract][Full Text] [Related]
34. Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL.
Zhang Q; Hu H; Chen SY; Liu CJ; Hu FF; Yu J; Wu Y; Guo AY
Genomics Proteomics Bioinformatics; 2019 Apr; 17(2):190-200. PubMed ID: 31201998
[TBL] [Abstract][Full Text] [Related]
35. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
36. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
37. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
[TBL] [Abstract][Full Text] [Related]
38. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
Gargett T; Brown MP
Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
[TBL] [Abstract][Full Text] [Related]
39. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
[TBL] [Abstract][Full Text] [Related]
40. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
